Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients

Proteasome inhibitors (PIs) are highly active in multiple myeloma (MM) but resistance is commonly observed. All clinical stage PIs effectively inhibit chymotrypsin‐like (CT‐L) activity; one possible mechanism of resistance is compensatory hyperactivation of caspase‐like (C‐L) and trypsin‐like (T‐L)...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Haematol
Main Authors: Levin, Nancy, Spencer, Andrew, Harrison, Simon J., Chauhan, Dharminder, Burrows, Francis J., Anderson, Kenneth C., Reich, Steven D., Richardson, Paul G., Trikha, Mohit
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2016
Assuntos:
Haematological Malignancy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5084787/
https://ncbi.nlm.nih.gov/pubmed/27161872
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.14113
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados